search
Back to results

Improving Drop Instillation Comfort of a Cyclosporine A Solution

Primary Purpose

Dry Eye Disease

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
0.09% cyclosporine A ophthalmic solution
Sponsored by
University of Waterloo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Dry Eye Disease focused on measuring dry eye disease, cyclosporine, eye drop

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Over 18 years of age. Ocular Surface Disease Index score >= 23. Strip meniscometry < 5 mm. Exclusion Criteria: Contact lens wearers. Have corneal neuropathic or neurotrophic disease. Have an ocular or medical condition or taking medications that could confound a study outcome. Currently pregnant or breastfeeding (cyclosporine is a FDA pregnancy Category C drug). Have an ocular or medical condition for which Cequa is contraindicated (e.g., allergy to cyclosporine or other ingredients in Cequacurrent eye infection, cancer or precancerous condition in or around the eyes). Have an allergy to fluorescein.

Sites / Locations

  • University of WaterlooRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

All participants

Arm Description

All participants will have a refrigerated 0.09% cyclosporine drop instilled in one eye, and a non-refrigerated 0.09% cyclosporine drop instilled in the other eye. The eye that receives the refrigerated drop is randomly determined.

Outcomes

Primary Outcome Measures

Ocular discomfort score. A subjective questionnaire that queries participants' ocular discomfort. The instrument ranges from 0 (no discomfort) to 10 (maximum discomfort).
Difference in ocular discomfort between the eye that receives a refrigerated Cequa drop and the eye that receives a non-refrigerated (room temperature) drop.

Secondary Outcome Measures

Full Information

First Posted
June 15, 2023
Last Updated
July 13, 2023
Sponsor
University of Waterloo
Collaborators
Sun Pharmaceutical Industries Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05957211
Brief Title
Improving Drop Instillation Comfort of a Cyclosporine A Solution
Official Title
Improving Drop Instillation Comfort of a Cyclosporine A Solution
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 19, 2023 (Actual)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Waterloo
Collaborators
Sun Pharmaceutical Industries Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients who suffer from dry eye disease are often prescribed eye drops containing cyclosporine A that help with reducing inflammation. The newest eye drop containing cyclosporine A is called Cequa (Sun Pharma, Canada). Unfortunately, nearly a quarter of (24.2%) of patients using Cequa have reported some form of discomfort (burning and stinging) when instilling the drops. This potentially discourages patients from continuing the eye drop, which prevents their dry eye disease from being managed effectively. This study is trying to determine if refrigerating the eye drops would allow the drops to feel more comfortable when they are instilled in the eye.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Disease
Keywords
dry eye disease, cyclosporine, eye drop

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
All participants
Arm Type
Experimental
Arm Description
All participants will have a refrigerated 0.09% cyclosporine drop instilled in one eye, and a non-refrigerated 0.09% cyclosporine drop instilled in the other eye. The eye that receives the refrigerated drop is randomly determined.
Intervention Type
Drug
Intervention Name(s)
0.09% cyclosporine A ophthalmic solution
Other Intervention Name(s)
Cequa
Intervention Description
Cequa is an ophthalmic solution used to treat moderate to severe dry eye disease. The typical dosage is one drop in each eye, twice a day. The drug is packaged in sterile, single use bottles.
Primary Outcome Measure Information:
Title
Ocular discomfort score. A subjective questionnaire that queries participants' ocular discomfort. The instrument ranges from 0 (no discomfort) to 10 (maximum discomfort).
Description
Difference in ocular discomfort between the eye that receives a refrigerated Cequa drop and the eye that receives a non-refrigerated (room temperature) drop.
Time Frame
Within 10 minutes of drop instillation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Over 18 years of age. Ocular Surface Disease Index score >= 23. Strip meniscometry < 5 mm. Exclusion Criteria: Contact lens wearers. Have corneal neuropathic or neurotrophic disease. Have an ocular or medical condition or taking medications that could confound a study outcome. Currently pregnant or breastfeeding (cyclosporine is a FDA pregnancy Category C drug). Have an ocular or medical condition for which Cequa is contraindicated (e.g., allergy to cyclosporine or other ingredients in Cequacurrent eye infection, cancer or precancerous condition in or around the eyes). Have an allergy to fluorescein.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
William Ngo, OD PhD
Phone
519-888-4567
Ext
40857
Email
wngo@uwaterloo.ca
Facility Information:
Facility Name
University of Waterloo
City
Waterloo
State/Province
Ontario
ZIP/Postal Code
N2J 3G1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Ngo, OD PhD
Phone
5198884567
Ext
40857
Email
wngo@uwaterloo.ca

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Improving Drop Instillation Comfort of a Cyclosporine A Solution

We'll reach out to this number within 24 hrs